Enlivex Therapeutics (TASE:ENLV), (NASDAQ: ENLV) is a biotechnology company focused on developing novel therapies for severe medical conditions with unmet needs, including sepsis, COVID-19, and solid tumors. Its operations span from early-stage preclinical research to advanced clinical trials, aiming to harness the body's immune system to fight these critical conditions more effectively. Enlivex's projects include Allocetra™, an innovative immunotherapy designed to rebalance the immune system in life-threatening situations. The objective of Enlivex is to advance its pipeline of treatments through clinical development, striving to provide new solutions for patients facing diseases with limited treatment options.